Core Viewpoint - The stock of Precision Medical-B (02675) surged over 12% following the release of a new surgical robot pricing guideline by the National Healthcare Security Administration, indicating strong market potential for the surgical robot industry in China and globally [1] Industry Summary - The surgical robot industry is experiencing rapid growth driven by technological innovation, clinical demand, and favorable policies, particularly in the single-port and natural orifice robot segments in China [1] - Analysts recommend focusing on domestic surgical robot manufacturers for import substitution and international expansion opportunities [1] Company Summary - Precision Medical's multi-port laparoscopic surgical robot was commercialized in December 2022, and by 2024, the company sold 20 units in China, ranking first among domestic manufacturers [1] - The company is set to accelerate its international expansion starting in 2025, with a significant increase in overseas orders; as of the end of 2025, 72 out of 118 global sales agreements for core products are with foreign countries [1]

Core Viewpoint - The recent issuance of a surgical robot charging guideline by the National Healthcare Security Administration is expected to benefit the surgical robot industry, leading to significant growth in both global and Chinese markets, particularly in the single-port and natural orifice robot segments [1] Group 1: Company Performance - Precision Medical-B (02675) saw its stock price increase by over 12%, reaching 64.85 HKD with a trading volume of 35.17 million HKD [1] - Since the commercialization of its multi-port laparoscopic surgical robot in December 2022, Precision Medical has sold 20 units in China by 2024, ranking first among domestic surgical robot manufacturers [1] Group 2: Industry Trends - The surgical robot industry is experiencing rapid growth due to technological innovation, clinical demand, and policy support, with a particular emphasis on the growth of domestic manufacturers in the import substitution and international expansion processes [1] - As of the end of 2025, Precision Medical has signed global sales agreements for 118 units of its core products, with 72 units designated for overseas markets, indicating a significant increase in international orders [1]

Investment Rating - The report assigns an "Accumulate" rating to the company [1][11][6]. Core Insights - The company is a leader in domestic surgical robotics, driving advancements in surgical procedures through continuous technological innovation. With rapid growth in global clinical surgical volumes, the company is experiencing significant revenue growth alongside increasing domestic sales and commercialization in overseas markets [2][11]. Summary by Sections 1. Domestic Surgical Robotics Leader - The company was founded in May 2017 in Shenzhen and is the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots. It has developed a "three-in-one" surgical solution combining multi-port, single-port, and remote systems [15][16]. - The company has achieved the highest sales volume among domestic manufacturers in 2024, with its multi-port surgical robot commercialized in December 2022, selling 20 units in China and covering over 220 hospitals across 30 provinces [11][29]. - Revenue is projected to grow from RMB 0.48 billion in 2023 to RMB 1.6 billion in 2024, with significant increases in sales volume and market acceptance [29][30]. 2. Clinical Advantages of Surgical Robots - Surgical robots provide significant clinical benefits, including high precision, stability, and repeatability, which traditional laparoscopic surgeries struggle to achieve. This technology is transforming the traditional surgical model [38][39]. - The company’s robots can be applied across various departments, addressing multiple clinical challenges and enhancing surgical outcomes [40][41]. 3. International Expansion and Orders - The company has successfully entered overseas markets, securing five orders in 2024 and establishing a distribution network across five continents. By the end of 2025, it had signed global sales agreements for 118 units, with 72 units designated for international markets [11][12]. - The internationalization strategy marks a transition from initial market testing to large-scale expansion [11][12]. 4. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are RMB 4.32 billion, RMB 8.11 billion, and RMB 12.36 billion, respectively, reflecting a growth rate of 233%, 170%, and 88% [4][11]. - The company is expected to turn profitable by 2026, with net profit projections of RMB 25 million in 2026 and RMB 167 million in 2027 [4][11]. 5. Management Team and R&D Strength - The management team has extensive experience in the surgical robotics industry, contributing to the company's rapid growth and innovation. The company has a robust R&D team of 265 members and holds the highest number of patents in the Chinese surgical robotics sector [20][25].

Group 1 - The core viewpoint of the report is that Jingfeng Medical-B (02675) is rated as "Buy" with projected revenues of 4.32 billion, 8.11 billion, and 12.36 billion yuan for 2025-2027, respectively, and a target price of 73.20 yuan/79.57 HKD based on a 35X PS for 2026 [1] - Jingfeng Medical is a leader in the domestic surgical robot market, continuously innovating to drive technological advancements, having established a "three-in-one" surgical solution with multi-port, single-port, and natural orifice surgical robots [1] - The company has achieved significant milestones, being the first in China and the second globally to obtain regulatory approval for multiple types of surgical robots, with its MSP2000 system receiving CE certification in October 2025 [1] Group 2 - Since the commercialization of its multi-port surgical robot in December 2022, Jingfeng Medical has sold 20 units in 2024, ranking first among domestic manufacturers, with clinical applications covering over 220 hospitals across 30 provinces [2] - The company's total revenue is projected to increase from 48 million yuan in 2023 to 160 million yuan in 2024, and from 30 million yuan in H1 2024 to 149 million yuan in H1 2025 [2] Group 3 - In 2024, Jingfeng Medical successfully entered the overseas market, quickly securing 5 orders and establishing a global distribution network covering five continents [3] - By H1 2025, the company had 30 distributors, including 10 overseas, and signed global sales agreements for 118 units of core products, with 72 units designated for international markets, marking a significant step in its globalization efforts [3]

Core Viewpoint - Cathay Securities initiates coverage on Precision Medical-B (02675) with a "Buy" rating, forecasting revenues of 432 million, 811 million, and 1.236 billion yuan for 2025-2027, respectively, and sets a target price of 73.20 yuan/79.57 HKD for 2026 based on a 35X PS ratio [1] Group 1: Company Overview - Precision Medical, founded in May 2017 in Shenzhen, is a leader in China's surgical robot sector, being the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [1] - The company has developed a "three-in-one" surgical solution that includes multi-port, single-port, and remote systems, with its globally pioneering MSP2000 multi-port surgical robot system receiving CE certification in October 2025 [1] Group 2: Market Performance - Since the commercialization of its multi-port surgical robot in December 2022, Precision Medical sold 20 units in China in 2024, ranking first among domestic manufacturers, with clinical applications covering over 220 hospitals across 30 provinces [2] - The company's total revenue is projected to increase from 48 million yuan in 2023 to 160 million yuan in 2024, and from 30 million yuan in H1 2024 to 149 million yuan in H1 2025 [2] Group 3: International Expansion - In 2024, Precision Medical successfully entered the overseas market, securing 5 orders and establishing a global sales team covering five continents [3] - By H1 2025, the company had 30 distributors, including 10 overseas, and signed global sales agreements for 118 core products, with 72 units designated for international markets, marking a significant step in its globalization efforts [3]

Investment Rating - The report assigns an "Accumulate" rating to the company [1][11][6]. Core Insights - The company is a leader in domestic surgical robotics, driving advancements in surgical procedures through continuous technological innovation. With rapid growth in global clinical surgical volumes, the company is experiencing significant revenue growth alongside increasing domestic sales and commercialization in overseas markets [2][11]. Summary by Sections 1. Domestic Surgical Robotics Leader - The company was founded in May 2017 in Shenzhen and is the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots. It has developed a "three-in-one" surgical solution combining multi-port, single-port, and remote systems [15][11]. - The company has achieved the highest sales volume among domestic manufacturers in 2024, with 20 units of its multi-port surgical robot sold in China, covering over 220 hospitals across 30 provinces [11][29]. - Revenue is projected to grow from RMB 0.48 billion in 2023 to RMB 1.6 billion in 2024, driven by increased sales and market acceptance of its products [29][30]. 2. Clinical Advantages of Surgical Robots - Surgical robots provide significant clinical benefits, including high precision, stability, and repeatability, which traditional laparoscopic surgeries struggle to achieve. This technology is transforming the landscape of minimally invasive surgeries [38][39]. 3. International Expansion and Sales Growth - The company has successfully entered overseas markets, securing five orders in 2024 and establishing a distribution network across five continents. By the end of 2025, it had signed global sales agreements for 118 units, with 72 units designated for international markets [11][29]. - The company’s internationalization efforts have marked a transition from initial market testing to large-scale expansion [11][29]. 4. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are RMB 4.32 billion, RMB 8.11 billion, and RMB 12.36 billion, respectively, reflecting substantial growth rates of 170% and 88% in the following years [4][11]. - The company is expected to turn profitable by 2026, with net profit projected to reach RMB 167 million by 2027, following a loss of RMB 219 million in 2024 [4][11]. 5. Management Team and R&D Strength - The management team, led by experienced founders, has built a proprietary technology platform supported by a multidisciplinary R&D team of 265 members. The company holds the highest number of patents in the Chinese surgical robotics sector [20][25]. - The company has established a comprehensive technology platform based on seven proprietary core technology modules, enhancing its competitive edge in the market [26][27].

Group 1: IPO Highlights - Beijing Zhiyu Huazhang Technology Co., Ltd. (Zhiyu) officially listed on the Hong Kong Stock Exchange on January 8, 2026, under the stock code "2513," becoming the "first global large model stock" [2] - Zhiyu plans to issue 37,419,500 H-shares, with a public offering in Hong Kong receiving 1,159.46 times subscription and international offering receiving 15.28 times subscription, raising over 4.3 billion HKD at an issue price of 116.2 HKD per share [2] - Shanghai Tianshu Zhixin Semiconductor Co., Ltd. (Tianshu) also listed on January 8, 2026, under the stock code "9903," issuing 25,431,800 shares with a public offering subscription of 414.24 times and international offering of 10.68 times [5] - MiniMax Group Inc. (MiniMax) listed on January 9, 2026, under the stock code "0100," becoming the largest AI large model company by IPO scale in history [7] - Shenzhen Jingfeng Medical Technology Co., Ltd. (Jingfeng) listed on January 8, 2026, under the stock code "2675," issuing 27,722,200 H-shares with a public offering subscription of 1,091.94 times and international offering of 25.18 times [9] Group 2: Company Performance and Growth - Zhiyu has achieved a revenue growth from 0.57 million CNY in 2022 to 3.12 million CNY in 2024, with a compound annual growth rate (CAGR) of 130% [3] - Tianshu's revenue increased from 1.89 billion CNY in 2022 to 5.40 billion CNY in 2024, with a CAGR of 68.8% [6] - MiniMax's revenue grew from 3.5 million USD in 2023 to 30.5 million USD in 2024, representing a year-on-year increase of 782.2% [7] - Jingfeng's revenue for the first half of 2025 reached approximately 149 million CNY, a nearly 400% year-on-year increase [10] Group 3: Market Position and Future Outlook - Zhiyu is recognized as the largest independent large model vendor in China, with significant market advantages in the enterprise sector [4] - Tianshu's products have been deployed in over 900 instances across key sectors, indicating a strong market presence [6] - MiniMax has established a user base of over 2.12 million individuals and 130,000 enterprise clients across more than 200 countries [7] - Jingfeng's robotic surgical systems have been used in over 12,000 surgeries, indicating a growing integration into standard surgical practices [9]

Group 1: IPO Dynamics - Beijing Zhipu Huazhang Technology Co., Ltd. (Zhipu) officially listed on the Hong Kong Stock Exchange on January 8, 2026, with the stock code "2513," becoming the "first global large model stock" [3] - Zhipu plans to issue 37,419,500 H-shares, with a subscription rate of 1,159.46 times for public offerings in Hong Kong and 15.28 times for international offerings, raising over HKD 4.3 billion at an issue price of HKD 116.2 per share [3] - Zhipu's revenue from 2022 to 2024 is projected to grow from CNY 0.57 billion to CNY 3.12 billion, with a compound annual growth rate (CAGR) of 130% [4] Group 2: Market Position and Growth - The domestic large language model market is expected to grow 20 times in the next six years, with enterprise demand leading the way, providing Zhipu with a competitive advantage [5] - Zhipu's revenue is expected to exceed USD 100 million in 2025, with projections of approximately CNY 1.6 billion and CNY 2.7 billion for 2026 and 2027, respectively [5] Group 3: Other Companies' IPOs - Shanghai Tianshu Zhixin Semiconductor Co., Ltd. (Tianshu) also listed on January 8, 2026, with a total issuance of 25,431,800 shares and a subscription rate of 414.24 times for public offerings in Hong Kong [7] - Tianshu's revenue grew from CNY 1.89 billion in 2022 to CNY 5.40 billion in 2024, with a CAGR of 68.8% [9] - MiniMax Group Inc. (MiniMax) listed on January 9, 2026, with a total issuance of 29,197,600 shares, achieving a subscription rate of 1,837.17 times for public offerings in Hong Kong [10] - MiniMax's revenue is projected to grow from USD 3.5 million in 2023 to USD 30.5 million in 2024, with a year-on-year increase of 782.2% [11] Group 4: Financial Performance - Shenzhen Jingfeng Medical Technology Co., Ltd. (Jingfeng) listed on January 8, 2026, with a revenue of approximately CNY 1.49 billion in the first half of 2025, representing a nearly 400% year-on-year growth [14] - Hunan Mingming Hen Mang Commercial Chain Co., Ltd. (Mingming) achieved a retail sales volume of CNY 661 billion in the first three quarters of 2025, a year-on-year increase of 74.5% [17] - Hunan Sangnisendi Group Co., Ltd. (Sangnisendi) reported revenues of CNY 1.07 billion and CNY 2.45 billion for 2023 and 2024, respectively, with a year-on-year growth of 129.5% [24] Group 5: Industry Insights - The AI and semiconductor sectors are experiencing rapid growth, with companies like Zhipu and Tianshu leading innovations in large models and computing power [4][9] - The food and beverage retail sector is also expanding, with companies like Mingming and COMMUNE establishing significant market positions [17][21] - The medical technology field is advancing with companies like Jingfeng and DeShi Biotech focusing on robotic surgery and AI in medical imaging [14][35]

Core Insights - Three companies, Zhiyu, Tianshu Zhixin, and Jingfeng Medical-B, successfully listed on the Hong Kong Stock Exchange on January 8, 2026, with first-day gains of 13.17%, 8.44%, and 30.90% respectively [1][4]. Company Summaries - **Zhiyu**: As the world's first publicly listed company focused on a general artificial intelligence (AGI) foundational model, Zhiyu has gained significant attention from investors. The company, founded in 2019, has developed a 100 billion parameter model (GLM-130B) and supports over 8,000 institutional clients and approximately 80 million devices. It holds a 6.6% market share among independent general model developers in China, ranking first in the country and second globally based on projected 2024 revenue [5][6]. - **Tianshu Zhixin**: This company specializes in providing general GPU products and AI computing solutions across various industries. Its product lineup includes general GPU chips and customized AI computing solutions, with over 52,000 GPU products delivered to more than 290 clients across sectors such as finance, healthcare, and transportation. Tianshu Zhixin has achieved over 900 deployments and applications in critical fields, supporting industrial digital transformation [6][7]. - **Jingfeng Medical-B**: Established in 2017, Jingfeng Medical-B is a leading company in the surgical robotics sector. It is the first in China and the second globally to receive regulatory approval for multiple types of surgical robots. The company's core product, the Jingfeng multi-port laparoscopic surgical robot, received approval in December 2022 and has expanded its clinical applications. In 2024, it sold 20 units, ranking first among domestic surgical robot manufacturers [7][8]. Market Reception - All three companies experienced strong demand during their public offerings, with Zhiyu and Jingfeng Medical-B achieving over 1,000 times oversubscription in the public offering phase, while Tianshu Zhixin had an oversubscription of 414.24 times [8][9]. - The strong performance of these IPOs has contributed to a positive sentiment in the Hong Kong IPO market, with expectations that upcoming listings may also perform well [4][11]. Institutional Interest - The three companies attracted significant interest from institutional investors, with Zhiyu securing a diverse base of cornerstone investors, including major public funds and private equity firms, totaling HKD 2.98 billion in subscriptions [9][10]. - Tianshu Zhixin and Jingfeng Medical-B also have backing from prominent institutions such as UBS and the Abu Dhabi Investment Authority, indicating strong confidence in their business models and growth potential [10]. Upcoming Listings - The Hong Kong market is witnessing a surge in new listings, with additional companies set to debut shortly after the successful IPOs of Zhiyu, Tianshu Zhixin, and Jingfeng Medical-B [11][12].

Core Insights - The article highlights the emergence of Shenzhen-based Jingfeng Medical as a key player in the global surgical robot market, leveraging over 600 patents to reshape the competitive landscape dominated by foreign brands [1][2]. Company Overview - Jingfeng Medical, established in 2017, focuses on the design, research, and manufacturing of surgical robots, with a product matrix that includes multi-port and single-port laparoscopic surgical robots, as well as natural orifice surgical robots [2]. - The company is the first in China and the second globally to obtain regulatory approval for all three types of surgical robots, positioning its technology among the world's top tier [2]. Market Trends - The penetration rate of robotic-assisted laparoscopic surgery in China is currently low at 0.7% in 2024, with expectations to rise to 3.0% by 2033, compared to 21.9% in the U.S. in 2024, indicating significant growth potential for domestic companies like Jingfeng Medical [3]. Commercialization and Financial Performance - Jingfeng Medical began commercializing its multi-port laparoscopic surgical robot in December 2022, achieving a leading position in the domestic market with 20 units sold in 2024 [4]. - The company reported revenues of 48.04 million yuan in 2023, projected to increase to 160 million yuan in 2024, with a 400% year-on-year growth in the first half of 2025 [4][5]. - The revenue structure shows that 92.9% comes from surgical robot sales, with significant contributions from overseas markets, indicating successful global expansion [5]. Investment and Funding - Jingfeng Medical has raised over 2 billion yuan through six rounds of financing, attracting investments from notable institutions such as Sequoia China and Temasek [6]. - The recent IPO attracted a strong base of cornerstone investors, reflecting high market confidence in the company's technological capabilities and growth potential [6]. Competitive Landscape - The company has established a formidable competitive barrier with its complete product matrix of multi-port, single-port, and natural orifice surgical robots, being the only company in China and one of two globally to have all these products approved [8]. - The potential for high returns is emphasized, with expectations of continued growth driven by increased penetration of robotic-assisted surgeries and expansion into international markets [8].